- Home
- DXC vs IDYA Comparison
DXC vs IDYA Comparison
Compare DXC & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXC
- IDYA
- Stock Information
- Founded
- DXC 1959
- IDYA 2015
- Country
- DXC United States
- IDYA United States
- Employees
- DXC N/A
- IDYA N/A
- Industry
- DXC EDP Services
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- DXC Technology
- IDYA Health Care
- Exchange
- DXC Nasdaq
- IDYA Nasdaq
- Market Cap
- DXC 2.6B
- IDYA 2.3B
- IPO Year
- DXC N/A
- IDYA 2019
- Fundamental
- Price
- DXC $14.79
- IDYA $27.16
- Analyst Decision
- DXC Hold
- IDYA Buy
- Analyst Count
- DXC 6
- IDYA 14
- Target Price
- DXC $15.60
- IDYA $49.17
- AVG Volume (30 Days)
- DXC 1.5M
- IDYA 953.6K
- Earning Date
- DXC 07-31-2025
- IDYA 11-03-2025
- Dividend Yield
- DXC N/A
- IDYA N/A
- EPS Growth
- DXC 384.35
- IDYA N/A
- EPS
- DXC 2.05
- IDYA N/A
- Revenue
- DXC $12,794,000,000.00
- IDYA $7,000,000.00
- Revenue This Year
- DXC N/A
- IDYA $62.30
- Revenue Next Year
- DXC N/A
- IDYA $285.58
- P/E Ratio
- DXC $7.22
- IDYA N/A
- Revenue Growth
- DXC N/A
- IDYA N/A
- 52 Week Low
- DXC $12.24
- IDYA $13.45
- 52 Week High
- DXC $24.83
- IDYA $39.30
- Technical
- Relative Strength Index (RSI)
- DXC 61.92
- IDYA 70.30
- Support Level
- DXC $14.07
- IDYA $24.04
- Resistance Level
- DXC $14.62
- IDYA $25.39
- Average True Range (ATR)
- DXC 0.36
- IDYA 1.05
- MACD
- DXC 0.12
- IDYA 0.16
- Stochastic Oscillator
- DXC 83.77
- IDYA 99.45
About DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.